Safety and tolerability
Testavan® is a 2% transdermal testosterone gel and is indicated for the treatment of adult male hypogonadism.[1]
Treatment with Testavan® restores testosterone levels to within the normal range and provides sustained improvements in sexual function, QoL and fatigue while demonstrating a favourable safety and tolerability profiles. [1-4]
Testavan is well tolerated®
Testavan® offers a well-tolerated safety profile and favorable tolerability profile with low incidence of elevated PSA [1-4]
1
Favourable skin tolerability profile
The most common adverse event in trials was application site reactions (4%) which lasted up to 9 months. The majority of these were mild to moderate in severity. [1]
2
Low incidence of elevated PSA
Just 2% of patients had a PSA >0.1 nmol/L (n=7/339), with a mean change from baseline of 0.24 ± 0.67 ng/dL [1]
MedDRA system organ class
Common (>1/100 to <1/10)
General disorders and administration site conditions
Application site reaction (including rash, erythema, pruritus, dermatitis, dryness and skin irritation)
Investigations
Blood triglycerides increase/ hypertriglyceridemia, PSAincreased, red blood cell count increased, haematocrit increased
Vascular disorders
Hypertension
Uncommon adverse events (> 1/1000 to <1/100) include increased haemoglobin and headaches. [1]
No cases of overdose have been reported in clinical trials. [1]
Contraindications
Testavan® is contraindicated in the following cases: [1]
Hypersensitivity to the active substance, propylene glycol or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics.
Known or suspected carcinoma of the breast or the prostate
Testavan® is also not indicated for the treatment in women. [1]
Explore the other benefits Testavan® can offer your patients:
References
1. Testavan® Summary of Product Characteristics. Available from : https://www.medicines.org.uk/emc/product/13936/smpc . Last accessed : August 2022.
2. Belkoff L et al. Andrologia 2018;50(1):e12801.
3. Arver S et al. Andrology 2018;6(3):396–407.
4. Cunningham G et al. Endocr Pract 2017;23(5):557–565.
QoL = quality of life, PSA = prostate specific antigen.